ST-503
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ST-503, covering 2025-10-28 to 2025-10-28. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) [Phase 1, Phase 2]